Browsing Tag
China biotech
4 posts
CARsgen showcases early clinical results for CT0596 allogeneic BCMA CAR-T cell therapy in multiple myeloma
CARsgen unveils early CT0596 CAR-T trial results at ASH 2025, showing deep responses and strong tolerability in multiple myeloma. See what’s next for the therapy.
Simcere’s SIM0278 enters Phase II trial in China: Could IL-2 Treg fusion therapy transform atopic dermatitis care?
Simcere’s SIM0278 enters Phase II in China for atopic dermatitis. Explore how its IL-2 Treg selectivity could redefine treatment for autoimmune skin diseases.
Ivonescimab plus chemotherapy cuts disease progression risk by 40% in first-line squamous NSCLC, outperforming PD-1 rival in Akeso’s HARMONi-6 trial
Find out how Akeso’s ivonescimab plus chemotherapy achieved a 40 % risk reduction over a PD-1 inhibitor combo in squamous NSCLC—and why it’s shaking up the global oncology market!
InnoCare Pharma receives Chinese IND clearance for novel B7-H3 targeted ADC ICP-B794 to treat solid tumors
InnoCare Pharma gains Chinese IND approval for ICP-B794, a novel B7-H3 targeted ADC for solid tumors including lung and prostate cancer.